Search - tctmd.com

Displaying 61 - 80 of 120

Sort: Relevancy | Date

Presentation JIM 2020

Optimal LDL levels in patients with ACS undergoing PCI

Presenter: Giuseppe Musumeci

February 13, 2020

News Daily News

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Michael O'Riordan

February 10, 2020

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Conference News ESC 2019

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Yael L. Maxwell

August 31, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Conference News EAS 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Michael O'Riordan

June 07, 2019

News Conference News EAS 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Michael O'Riordan

June 05, 2019

News Conference News EAS 2019

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Michael O'Riordan

June 04, 2019

News Conference News SCAI 2019

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

Yael L. Maxwell

June 03, 2019

News Conference News EAS 2019

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

Michael O'Riordan

May 30, 2019

News Conference News EAS 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

Michael O'Riordan

May 29, 2019

News Daily News

Familial Hypercholesterolemia Seen in 10% of Young MI Patients

Michael O'Riordan

May 15, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Shelley Wood

November 05, 2018

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Shelley Wood

October 22, 2018

Advertisement

Optimal LDL levels in patients with ACS undergoing PCI

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Recurrent Events Common Among Young Patients With CAD

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

CHD Mortality Significantly Elevated in Patients With Severe FH

Familial Hypercholesterolemia Seen in 10% of Young MI Patients

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content